TRCT
INO icon

Tower Research Capital (TRC)’s Inovio Pharmaceuticals INO Stock Holding History

Tower Research Capital (TRC)’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.6K Buy
+55,491
New +$91.3K ﹤0.01% 2217
2025
Q3 		– Sell
-11,687
Closed -$23.8K – 5409
2025
Q2 		$23.8K Buy
11,687
+6,073
+108% +$11.6K ﹤0.01% 3581
2025
Q1 		$9.09K Sell
5,614
-2,876
-34% -$5.77K ﹤0.01% 3822
2024
Q4 		$15.5K Buy
8,490
+6,498
+326% +$28.8K ﹤0.01% 3402
2024
Q3 		$11.5K Sell
1,992
-3,892
-66% -$32.1K ﹤0.01% 3658
2024
Q2 		$47.5K Buy
5,884
+2,472
+72% +$26K ﹤0.01% 3141
2024
Q1 		$47.4K Buy
3,412
+1,778
+109% +$15.3K ﹤0.01% 2313
2023
Q4 		$10K Sell
1,634
-1,429
-47% -$7.05K ﹤0.01% 4310
2023
Q3 		$14.3K Sell
3,063
-47
-2% -$260 ﹤0.01% 3694
2023
Q2 		$16.7K Sell
3,110
-2,480
-44% -$20K ﹤0.01% 3547
2023
Q1 		$55K Buy
5,590
+3,719
+199% +$63.4K ﹤0.01% 2401
2022
Q4 		$35K Sell
1,871
-8,886
-83% -$201K ﹤0.01% 2609
2022
Q3 		$222K Buy
10,757
+5,426
+102% +$139K ﹤0.01% 1833
2022
Q2 		$110K Buy
5,331
+1,512
+40% +$42.6K ﹤0.01% 2209
2022
Q1 		$165K Sell
3,819
-3,103
-45% -$140K ﹤0.01% 1866
2021
Q4 		$414K Buy
6,922
+1,859
+37% +$149K 0.01% 1239
2021
Q3 		$435K Buy
5,063
+4,290
+555% +$431K 0.01% 1093
2021
Q2 		$86K Sell
773
-636
-45% -$61.1K ﹤0.01% 2545
2021
Q1 		$157K Buy
1,409
+942
+202% +$124K ﹤0.01% 2209
2020
Q4 		$50K Sell
467
-3,448
-88% -$459K ﹤0.01% 3125
2020
Q3 		$545K Buy
3,915
+2,044
+109% +$426K 0.01% 1588
2020
Q2 		$605K Buy
+1,871
New +$300K 0.02% 849
2019
Q4 		– Sell
-326
Closed -$8K – 3915
2019
Q3 		$8K Buy
326
+161
+98% +$4.89K ﹤0.01% 3078
2019
Q2 		$6K Buy
+165
New +$6.55K ﹤0.01% 2851
2019
Q1 		– Sell
-47
Closed -$2K – 4018
2018
Q4 		$2K Buy
+47
New +$2.85K ﹤0.01% 3372
2018
Q2 		– Sell
-1,151
Closed -$65K – 3854
2018
Q1 		$65K Buy
1,151
+1,038
+919% +$56.2K 0.01% 1528
2017
Q4 		$6K Sell
113
-536
-83% -$33.2K ﹤0.01% 2816
2017
Q3 		$49K Buy
+649
New +$48.3K ﹤0.01% 1989
2017
Q1 		– Sell
-326
Closed -$27K – 3460
2016
Q4 		$27K Buy
326
+284
+676% +$25.7K ﹤0.01% 1878
2016
Q3 		$5K Sell
42
-65
-61% -$7.18K ﹤0.01% 2550
2016
Q2 		$12K Buy
107
+92
+613% +$11.2K ﹤0.01% 2656
2016
Q1 		$2K Sell
15
-219
-94% -$16.9K ﹤0.01% 3388
2015
Q4 		$19K Sell
234
-4,592
-95% -$366K ﹤0.01% 1345
2015
Q3 		$335K Buy
4,826
+4,448
+1,177% +$388K 0.03% 198
2015
Q2 		$37K Sell
378
-503
-57% -$53.7K ﹤0.01% 1592
2015
Q1 		$86K Buy
+881
New +$85.4K 0.01% 1017
2014
Q4 		– Sell
-10
Closed -$1K – 4319
2014
Q3 		$1K Sell
10
-416
-98% -$51.8K ﹤0.01% 4098
2014
Q2 		$55K Sell
426
-354
-45% -$41.8K 0.01% 1240
2014
Q1 		$125K Sell
780
-69
-8% -$9.9K 0.02% 599
2013
Q4 		$119K Buy
+849
New +$85K 0.02% 769

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s INO Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Inovio Pharmaceuticals (INO) in Q1 2026: 55,491 shares worth $96.6K. The stake represents ﹤0.01% of the portfolio and ranks #2217 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in INO as recently as Q2 2025.

Tower Research Capital (TRC) first reported a position in INO in Q4 2013 and has held it in 40 quarters since. The position peaked at $605K in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Tower Research Capital (TRC) held 55,491 shares of Inovio Pharmaceuticals worth $96.6K as of Q1 2026.
  • Inovio Pharmaceuticals was a new Tower Research Capital (TRC) position in Q1 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2217 holding.
  • Tower Research Capital (TRC) first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 40 quarters since.
  • Tower Research Capital (TRC)'s Inovio Pharmaceuticals position peaked at $605K in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.